Metrics as of 10/17/2026, 08:52 AM (Berlin time), refresh in progress.
Madrigal Pharmaceuticals Stock
Madrigal Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- William J. Sibold
- Employees
- 915
- Market cap
- $10.4 B
- IPO
- 06/02/2007
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase based in West Conshohocken, USA. The company focuses its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Madrigal Pharmaceuticals stock: price history
1D
-2.2%
1W
-4.7%
1M
-15.0%
6M
-15.5%
YTD
-22.8%
1Y
+1.7%
2Y
+108.6%
5Y
+421.9%
10Y
+2,655.8%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~13% weaker price swings than usual
Ask the agents about Madrigal Pharmaceuticals
Analyst assessment of Madrigal Pharmaceuticals
PRICE TARGET LOW
US$542.00
CONSENSUS
US$686.44
MEDIAN
US$685.00
PRICE TARGET HIGH
US$962.00
0
STRONG BUY
22
BUY
2
HOLD
1
SELL
0
STRONG SELL
25
TOTAL · Buy
As of: 04/08/2026
Madrigal Pharmaceuticals stock metrics
P/E
-34.89
P/B
25.03
EV/EBITDA
-35.76
RETURN ON EQUITY
-11.1%
NET MARGIN
-15.9%
DEBT/EQUITY
0.66
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.2%
FLOAT SHARES
21,539,282
AVG. DAILY VOLUME (30D)
265,950
Insider transactions (SEC)
Sibold William John
Sibold William John
Sibold William John
Sibold William John
Sibold William John
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.2%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Madrigal Pharmaceuticals stock
What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is William J. Sibold, the company employs around 915 people.
The IPO was on 06/02/2007; the stock trades on NASDAQ under the ticker MDGL.
What do analysts say about Madrigal Pharmaceuticals stock?
25 analysts rate the stock, the consensus is Buy (as of 04/08/2026).
The average price target is US$686.44, ranging from US$542.00 to US$962.00, with a median of US$685.00.
This is an external assessment, not a statement by Market Jury.
When does Madrigal Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -13% stronger than usual.
Does Madrigal Pharmaceuticals pay a dividend?
No, Madrigal Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Madrigal Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Madrigal Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Madrigal Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.